Comparing of NewLink Genetics Corporation (NLNK) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) – MS Wkly

As Biotechnology companies, NewLink Genetics Corporation (NASDAQ:NLNK) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) are our subject to contrast. And more specifically their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Table 1 showcases the top-line revenue, earnings per share and valuation of NewLink Genetics Corporation and Brainstorm Cell Therapeutics Inc.

Profitability

Table 2 shows us NewLink Genetics Corporation and Brainstorm Cell Therapeutics Inc.s net margins, return on equity and return on assets.

Volatility & Risk

NewLink Genetics Corporations current beta is 1.31 and it happens to be 31.00% more volatile than Standard and Poors 500. Competitively, Brainstorm Cell Therapeutics Inc.s 19.00% volatility makes it more volatile than Standard and Poors 500, because of the 1.19 beta.

Liquidity

The current Quick Ratio of NewLink Genetics Corporation is 13.3 while its Current Ratio is 13.3. Meanwhile, Brainstorm Cell Therapeutics Inc. has a Current Ratio of 1 while its Quick Ratio is 1. NewLink Genetics Corporation is better positioned to pay off its short-term and long-term debts than Brainstorm Cell Therapeutics Inc.

Institutional and Insider Ownership

NewLink Genetics Corporation and Brainstorm Cell Therapeutics Inc. has shares held by institutional investors as follows: 34.6% and 11.4%. 0.1% are NewLink Genetics Corporations share held by insiders. On the other hand, insiders held about 0.6% of Brainstorm Cell Therapeutics Inc.s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year NewLink Genetics Corporation has stronger performance than Brainstorm Cell Therapeutics Inc.

Summary

NewLink Genetics Corporation beats on 7 of the 10 factors Brainstorm Cell Therapeutics Inc.

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. Its portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. The company is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer (NSCLC); and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors. Its clinical development products include NLG2101 for metastatic breast cancer; NLG2102 for refractory malignant brain tumors; NLG2103 for advanced melanoma; NLG2104 for metastatic pancreatic cancer; NLG2105 for pediatric patients with refractory malignant brain tumors; and NLG2106 for acute myelogenous leukemia. The companys HyperAcute cellular immunotherapy product candidates under clinical development include tergenpumatucel-L, is being investigated in Phase Ib/II clinical trial for patients with advanced NSCLC; and dorgenmeltucel-L, is being investigated in a Phase II clinical trial for patients with advanced melanoma. Its infectious disease program includes replication-competent recombinant vesicular stomatitis virus, a vaccine technology to treat Ebola and Marburg viruses. The company has license and collaboration agreements with Genentech, Inc. and Merck, Sharpe and Dohme Corp. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See more here:
Comparing of NewLink Genetics Corporation (NLNK) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly